The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats

Lipids in Health and Disease

Mona A Mohamed²  Aida M Ibrahim³  Soad M Abdel Gawad²  Amr Y Esmat¹  Fawzia M Refaie¹ 

[1] Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt;Department of Organic Chemistry, Faculty of Science, Al-Azhar University, Cairo, Egypt;Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

关键词: Rat;    lipoproteins;    Cholesterol;    Triglycerides;    Diabetes mellitus;    hypercholesterolemia;    Bezafibrate;    Halogenated quinazolinones;    Quinazolinone;   

Others  :  1213243
DOI  :  10.1186/1476-511X-4-22

 received in 2005-09-21, accepted in 2005-10-04,  发布年份 2005

【 摘 要 】

In the present study, the effects of subchronic treatments (4 weeks) of hypercholesterolemic (single) and diabetic-hypercholesterolemic (combined) rats with 4 (3H) quinazolinone and 2 halogenated derivatives (6, 8-dibromo-2-methy-4 (3H) quinazolinone and 6-iodo-2-methyl-4(3H) quinazolinone) at a sublethal dose level (2 mg/Kg) on cholesterol metabolism were investigated. Bezafibrate, a hypolipidemic drug was used as a reference compound for data comparison. Treatment of rats with single and combined hypercholesterolemia with quinazolinone compounds gave rise to highly significant reductions in serum total cholesterol and cholesterol ester levels, whereas serum triacylglycerol level was significantly reduced only after treatment with halogen-substituted quinazolinones in single hyper-cholesterolemia, compared to the control group. The effects of different quinazolinones and bezafibrate on reduction of serum LDL-C level were comparable in single hypercholesterolemia but significantly different in combined hypercholesterolemia. Results obtained from this study suggest that the antihyperlipidemic effect of quinazolinone compounds was brought about by inhibition of dietary cholesterol absorption and / or intestinal ACAT activity.

【 授权许可】

   
2005 Refaie et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Habib NS, Ismail KA, El-Tombary AA, Abd El-Aziem T: Antilipidemic agents, Part IV: Synthesis and antilipidemic testing of some heterocyclic derivatives of hexadecyl and cyclohexyl hemisuccinate esters. Pharmazie 2000, 55:495-499.
• [2]Fuster V, Alexander PW, O'Rourke RA, Roberts R, King SB, Wellens HJ: Atherogenesis and its determinants. In Hurst's the heart. Volume 3. 10th edition. New York, Mc Graw-Hill; 2001::1065.
• [3]Devlin T: Textbook of biochemistry with clinical correlations. 3rd edition. New York, Wiley-Liss Inc; 1995:376-381.
• [4]McNamara DJ: Dietary cholesterol and atherosclerosis. Biochim Biophys Acta 2000, 1529:310-320.
• [5]Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003, 5:19-27.
• [6]Koschinsky ML, Marcoina SM: The relationship between lipoprotein alpha and the complications of diabetes mellitus. Acta Diabet 2003, 40:65-76.
• [7]Kunes J, Bazant J, Pour M, Waisser K, Slosarek M, Janota J: Quinazoline derivatives with antitubercular activity. IL Farmaco 2000, 55:725-729.
• [8]Magnus NA, Confalone PN, Storace L, Patel M, Wood CC, Davis WP, Parsons RL: General scope of 1,4-Diasteoselective additions to a 2(3H)- quinazolinone: Practical preparation of HIV therapeutics. J Org Chem 2003, 68:754-61.
• [9]Jantova S, Urbancikova M, Maliar T, Mikuldsova M, Rauko P, Cipak L, Kubikova J, Stankovsky S, Spirkova K: Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasm 2001, 48:52-60.
• [10]Chern J, Tao P, Wang K, Gutcait A, Liu S, Yen M, Chien S, Rong J: Studies on quinazolines and 1, 2, 4-benzothiadiazine 1, 1-dioxides. Synthesis and pharmacological evaluation of tricyclic fused quinazolines and 1,2, 4-benzothiadiazine 1,1,-dioxides as potential alpha 1-adrenoceptor antagonists. J Med Chem 1998, 41:3128-3141.
• [11]Santagati A, Modica M, Santagati M, Cutuli VM, Mangano NG, Caruso A: Synthesis and pharmacological screening of 1, 3, 4-thiadiazino [2,3-b]quinazoline derivatives. Pharmazie 2000, 55:737-739.
• [12]Kurogi Y, Inoue Y, Tsutsumi K, Nakamura S, Nagao K, Yoshitsugu H, Tsuda Y: Synthesis and hypolipidemic activities of novel 2-(4-[(diethoxyphosphoryl) methyl]phenyl) quinazolines and 4(3H)- quinazolinones. J Med Chem 1996, 39:1433-37.
• [13]Parkanyi C, Schmidt DS: Synthesis of 5- chloro -2- methyl- 3- (5- methylthiazol -2-yl) – 4(3H) quinazolinone and related compounds with potential biological activity. J Heterocyclic Chem 2000, 37:725-729.
• [14]Paget GE, Barnes JM: Evaluation of drug activities. In Pharmacometrics. Volume 1. Edited by Laurence DR, Bacharach AL. London, Academic Press; 1964::50.
• [15]Maillard J, Benard M, Vincent M, Tri V, Jolly R: Dérivés de la (3H) quinazolinone-4-doués de propiétés anti-inflammatoire. Chimie Thérape 1967, 3:202-12.
• [16]Seki K, Watanabe T, Suga T: Influence of the new antihypertensive drug, SM-2470 (a quinazoline derivative), on cholesterol metabolism in rats. J Pharm Pharmacol 1987, 39:904-910.
• [17]Sheweita SA, Newairy AA, Mansour HA, Youssif MI: Effect of some hypoglycemic herbs on the activity of phase I and II drug – metabolizing enzymes in alloxan- induced diabetic rats. Toxicology 2002, 174:131-39.
• [18]Trinder P: Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann Clin Biochem 1969, 6:24-28.
• [19]Zlatkis A, Zak B, Boyle AJ: A new method for the direct determination of serum cholesterol. J Lab Clin Med 1953, 41:486-92.
• [20]Jacobs NJ, Van Denmark PJ: The purification and properties of the alpha-glycerophosphate-oxidizing enzyme of Streptococcus faecalis 10 C1. Arch Biochem Biophys 1960, 88:250-55.
• [21]Knight JA, Anderson S, Rawle JM: Chemical basis of the sulfo-phospho-vanillin reaction of estimating total serum lipids. Clin Chem 1972, 18:199-204.
• [22]Assmann G, Schriewer H, Schmitz G, Hagele EO: Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983, 29:2026-2030.
• [23]Kerscher L, Schiefer S, Draeger B, Maier J, Ziegenhorn J: Precipitation methods for the determination of LDL-cholesterol. Clin Biochem 1985, 18:118-125.
• [24]Freidwald WT, Levy RJ, Fredrickson DS: Estimation of the concentration of the preparative ultracentrifuge. Clin Chem 1972, 18:499-509.
• [25]Bok SH, Lee SH, Park YB, Bae KH, Son KH, Jeong TS, Choi MS: Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: Cholesterol transferase is lower in rats fed citrus pee extract or a mixture of citrus bioflavonoids. J Nutr 1999, 129:1182-85.
• [26]Gottfried SP, Rosenberg B: Improved manual spectrophotometric procedure for determination of serum triglycerides. Clin Chem 1973, 19:1077-1080.
• [27]Esterbauer H, Cheeseman KH: Determination of aldehyde lipid peroxidation products: Malonaldehyde and 4-hydroxynonenal. Methods in Enzymology 1990, 186:407-10.
• [28]Williams B Biostatistics, Chapman & Hall, London; 1993.
• [29]Wu H, Johnston P, Seu W, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YD, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990, 13:1-10.
• [30]Sellei C, Hardt E, Nemeth L: "Chemotherapy of neoplastic diseases". Budapest, Akademiai Kiado, The Publishing House of the Hungarian Academy of Science; 1970:35-45.
• [31]Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845-4852.
• [32]Feron VJ, de Groot AP, Spanjers MT, Til HP: An evaluation of the criterion "organ weight" under conditions of growth retardation. Food Cosmet Toxicol 1973, 11:85-94.
• [33]Gallo L, Bennett C, Myers S, Vanouny G: Cholesterol absorption in rat intestine: Role of cholesterol esterase and ACAT. J Lipid Res 1984, 25:604-12.
• [34]Park YB, Jeon SM, Byun SJ, Kim HS, Choi MS: Absorption of intestinal free cholesterol is lowered by supplementation of Areca catechu L. extract in rats. Life Sci 2002, 70:1849-1859.
• [35]Nelson DL, Cox MM: Lehninger Principles of Biochemistry. 3rd edition. New York, Worth Publisher; 2000:800-805.
• [36]Yano M, Inoune M, Maehata F, Shiba T, Yamakado M, Hirabayashi Y, Taniyama M, Suzuki S: Increased electronegative charge of serum low density lipoprotein in patients with diabetes mellitus. Clin Chim Acta 2004, 340:93-98.
• [37]Peng IH, Sheu JR, Chern JW, Lee YM, Yen MH: Antihypertensive and hypolipidaemic effects of DC-015, a novel potent and specific α1 adrenoceptor antagonist: Comparison with prazocin in spontaneously hypertensive rats. J Biomed Sci 1996, 3:108-116.
• [38]Carr TP, Parks JS, Rudel LL: Hepatic ACAT activity in African green monkeys is highly correlated to plasma LDL cholesteryl esters enrichment and coronary artery atherosclerosis. Atheroscler Thromb 1992, 12:1274-83.
• [39]Carr TP, Hamilton RL, Rudel LL: ACAT inhibitors decrease secretion of CE and apo B by perfused livers of African green monkeys. J Lipid Res 1995, 36:25-36.